(Q48208532)

English

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

Toni K Choueiri

12

object named as

Toni K Choueiri

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

author name string

Aymen A Elfiky

1

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

Daniel C Cho

2

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

David F McDermott

3

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

Jonathan E Rosenberg

4

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

Barry Fortner

5

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

Lucia Antràs

6

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

Kristina Chen

7

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

Mei Sheng Duh

8

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

Sujata S Jayawant

9

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

William K Oh

10

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

Michael B Atkins

11

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

publication date

6 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

Urologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

29

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

6

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

756-763

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.01.008

7 January 2021

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.01.008

7 January 2021

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.01.008

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.01.008

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.01.008

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.01.008

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.01.008

7 January 2021

Sequential sorafenib and sunitinib for renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.01.008

7 January 2021

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.01.008

7 January 2021

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.01.008

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.01.008

7 January 2021

Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.01.008

7 January 2021

Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.01.008

7 January 2021

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.01.008

7 January 2021

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.01.008

7 January 2021

Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.01.008

7 January 2021

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.01.008

7 January 2021

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.01.008

7 January 2021

Identifiers

10.1016/J.UROLONC.2010.01.008

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

release_fiusa2sozffzdgo7nldj7ex2zy

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20451414

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48208532&oldid=2190634876"